The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
Miguel J. Sotelo
No relevant relationships to disclose
Luis Manso
No relevant relationships to disclose
José Ángel Garcia Saenz
No relevant relationships to disclose
Eva M. Ciruelos
No relevant relationships to disclose
Fernando Moreno
No relevant relationships to disclose
Cesar Mendiola
No relevant relationships to disclose
Hector Callata
No relevant relationships to disclose
Ismael Ghanem
No relevant relationships to disclose
Santiago Cabezas
No relevant relationships to disclose
Jose-Luis Gonzalez-Larriba
No relevant relationships to disclose
Eduardo Diaz Rubio
No relevant relationships to disclose